At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 2, 2026 at 16:18 ET
BD filed recast historical financial information reflecting the spin-off of its Biosciences and Diagnostic Solutions business (completed Feb 9, 2026) as discontinued operations. The recast New BD continuing operations show Q1 fiscal 2026 revenue of $4.486B, up 3.5% reported and 2.5% on a currency-neutral basis versus the prior-year recast period, with adjusted diluted EPS from continuing operations of $2.50, down from $2.78 in the year-ago period.
- BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation on February 9, 2026.
- Recast New BD continuing operations Q1 fiscal 2026 revenue: $4.486B, up 3.5% reported and 2.5% FXN vs. $4.333B in the prior-year recast period.
- Recast New BD continuing operations adjusted diluted EPS (non-GAAP) for Q1 fiscal 2026: $2.50, down from $2.78 in the prior-year recast period.
- GAAP diluted EPS from continuing operations for recast New BD: $1.09 vs. $0.50 in the prior-year recast period.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access